Ramachandran argues compounders should have to report side effects for peptides she says lack evidence of efficacy, safety and quality.
Recap by typeshit. Post by Reshma Ramachandran on X.
Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
Post hoc REDEFINE 1 data held up in premenopausal, perimenopausal and postmenopausal women, versus low single digits on placebo.
Reuters reports the Indian drugmaker widened its generic semaglutide lineup, based on product photos and marketing material it reviewed.
Loading…